AR038235A1 - Compuestos de espiropiperidina n-sustituidos como ligandos para el receptor orl-1 - Google Patents

Compuestos de espiropiperidina n-sustituidos como ligandos para el receptor orl-1

Info

Publication number
AR038235A1
AR038235A1 ARP030100227A ARP030100227A AR038235A1 AR 038235 A1 AR038235 A1 AR 038235A1 AR P030100227 A ARP030100227 A AR P030100227A AR P030100227 A ARP030100227 A AR P030100227A AR 038235 A1 AR038235 A1 AR 038235A1
Authority
AR
Argentina
Prior art keywords
alkyl
substituted
independently selected
hydroxy
alkoxy
Prior art date
Application number
ARP030100227A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AR038235A1 publication Critical patent/AR038235A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Abstract

Estos compuestos son ligandos para el receptor ORL-1 y especialmente son antagonistas del citado receptor. Reivindicación 1: Un compuesto de la siguiente fórmula (1): o una sal o solvato farmacéuticamente aceptable del mismo, caracterizado porque R1 a R12 se seleccionan independientemente del grupo constituido por hidrógeno; halo; hidroxi; alquilo C1-6; alquilo C1-6 sustituido con uno a cinco halos que pueden ser iguales o diferentes; alquilo C1-6 sustituido con uno a cinco sustituyentes independientemente seleccionados del grupo constituido por hidroxi, amino, [alquil C1-6]NH-, [alquil C1-6]2N-, H2NC(=O)-, [alquil C1-6]NHC(=O)-, [alquil C1-6]2NC(=O)-, alcoxi C1-6 y un heterociclilo de cinco a seis miembros totalmente saturado que contiene de uno a dos heteroátomos independientemente seleccionados de nitrógeno y oxígeno; alcoxi C1-6; alcoxi C1-6 sustituido con uno a cinco halos que pueden ser iguales o diferentes; alcoxi C1-6 sustituido con uno a cinco sustituyentes independientemente seleccionados del grupo constituido por hidroxi, amino, [alquil C1-6]NH-, [alquil C1-6]2N-, H2NC(=O)-, [alquil C1-6]NHC(=O)- y [alquil C1-6]2NC(=O)-; amino; carboxi; [alcoxi C1-6]C(=O)-; H2NC(=O)-; [alquil C1-6]NHC(=O)-; [alquil C1-6]NHC(=O)- en el que el citado alquilo C1-6 está sustituido con un hidroxi; [alquil C1-6]2NC(=O)-, [alquil C1-6]2NC(=O)-, en el que uno o ambos de los alquilo C1-6 están sustituidos con un hidroxilo; arilo seleccionados de fenilo y naftilo; y un heterociclilo de cuatro a ocho miembros que contiene de uno a cuatro heteroátomos en el anillo independientemente seleccionados de nitrógeno, oxígeno y azufre; o de los grupos R1, R2, R3 y R4 tomados conjuntamente forman -CH2- o -(CH2)2-, y los dos grupos restantes se definen como anteriormente; X1 y X2 se seleccionan independientemente de CH2; CH-hidroxi; O; NH; S; C(=O); SO2 y [alquil C1-6]N; o X1 y X2 tomados conjuntamente forman CH=CH; R13 se selecciona del grupo constituido por hidrógeno; hidroxi; alquilo C1-6; alquilo C1-6 sustituido con uno a cinco halos que pueden ser iguales o diferentes; y alquilo C1-6 sustituido con uno a cinco sustituyentes independientemente seleccionados del grupo constituido por hidroxi, amino, [alquil C1-6]NH-, [alquil C1-6]2N-, H2NC(=O)-, [alquil C1-6]NHC(=O)-, [alquil C1-6]2NC(=O)-, alcoxi C1-6 y un heterociclilo de cinco a seis miembros totalmente saturado que contiene de uno a dos heteroátomos independientemente seleccionados de nitrógeno y oxígeno; o R12 y R13 tomados conjuntamente con los tres átomos de anillo del anillo de dihidroquinolina o tetrahidroquinolina que separa los citados sustituyentes forman un anillo de cinco a siete miembros que está parcial o totalmente insaturado, en el que el átomo de anillo no compartido con el anillo de dihidroquinolina o tetrahidroquinolina y adyacente al átomo de nitrógeno en el anillo de dihidroquinolina o tetrahidroquinolina es un átomo de carbono; los restantes uno a tres átomos de anillo no compartidos con el anillo de dihidroquinolina o tetrahidroquinolina son átomos de carbono, estando opcionalmente reemplazado uno de los citados átomos de carbono por un átomo de nitrógeno, oxígeno o azufre; y uno o dos de los átomos de carbono y nitrógeno no compartidos con el anillo de dihidroquinolina o tetrahidroquinolina están opcionalmente sustituidos con sustituyentes independientemente seleccionados de oxo; hidroxi; alquilo C1-6; alquilo C1-6 sustituido con uno a cinco halos que pueden ser iguales o diferentes; alquilo C1-6 sustituido con uno a cinco sustituyentes independientemente seleccionados del grupo constituido por hidroxi, amino [alquil C1-6]NH-, [alquil C1-6]2N-, -H2NC(=O)-, [alquil C1-6]NHC(=O)-, alcoxi C1-6 y un heterociclilo de cinco a seis miembros totalmente saturado que contiene de uno a dos heteroátomos independientemente seleccionados de nitrógeno y oxígeno; alcoxi C1-6; alcoxi C1-6 sustituido con uno a cinco halos que pueden ser iguales o diferentes; alcoxi C1-6 sustituido con uno a cinco sustituyentes independientemente seleccionados del grupo constituido por hidroxi, amino, [alquil C1-6]NH-, [alquil C1-6]2N-, H2NC(=O)-, [alquil C1-6NHC(=O)- y [alquil C1-6]2NC(=O)-, amino; ambos R14 y R15 son hidrógeno o tomados conjuntamente forman un grupo oxo y la línea de trazos representa un enlace sencillo o doble.
ARP030100227A 2002-01-28 2003-01-27 Compuestos de espiropiperidina n-sustituidos como ligandos para el receptor orl-1 AR038235A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35243702P 2002-01-28 2002-01-28

Publications (1)

Publication Number Publication Date
AR038235A1 true AR038235A1 (es) 2005-01-05

Family

ID=27663095

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030100227A AR038235A1 (es) 2002-01-28 2003-01-27 Compuestos de espiropiperidina n-sustituidos como ligandos para el receptor orl-1

Country Status (13)

Country Link
US (1) US6869960B2 (es)
EP (1) EP1470126A1 (es)
JP (1) JP2005519921A (es)
AR (1) AR038235A1 (es)
BR (1) BR0307268A (es)
CA (1) CA2466915A1 (es)
GT (1) GT200300014A (es)
MX (1) MXPA04007242A (es)
PA (1) PA8564201A1 (es)
PE (1) PE20030848A1 (es)
TW (1) TW200302725A (es)
UY (1) UY27623A1 (es)
WO (1) WO2003064425A1 (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6374762B1 (en) * 1997-10-27 2002-04-23 Correct Craft, Inc. Water sport towing apparatus
KR20050043935A (ko) 2002-09-09 2005-05-11 얀센 파마슈티카 엔.브이. Ｏｒｌ-1 수용체 매개 장애의 치료에 유용한 하이드록시 알킬 치환된 1,3,8-트리아자스피로[4.5]데칸-4-온 유도체
ITMI20031349A1 (it) * 2003-07-01 2005-01-02 Ufpeptides S R L Antagonisti del recettore nop e loro usi terapeutici.
WO2005016913A1 (en) * 2003-08-19 2005-02-24 Pfizer Japan, Inc. Tetrahydroisoquinoline or isochroman compounds as orl-1 receptor ligands for the treatment of pain and cns disorders
CN1930145B (zh) * 2004-03-05 2011-06-15 Msdk.K.公司 环烷吡啶衍生物
CA2563164A1 (en) * 2004-03-29 2005-10-06 Pfizer Inc. Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as orl1-receptor antagonists
WO2005117862A1 (en) * 2004-06-03 2005-12-15 Pfizer Limited, Treatment of urinary conditions including incontinence
US7786141B2 (en) * 2004-08-19 2010-08-31 Vertex Pharmaceuticals Incorporated Dihydrospiroindene modulators of muscarinic receptors
EP1781288A2 (en) * 2004-08-19 2007-05-09 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
RU2007124373A (ru) * 2004-11-29 2009-01-10 Вертекс Фармасьютикалз Инкорпорейтед (Us) Модуляторы мускариновых рецептеров
MY145694A (en) 2005-04-11 2012-03-30 Xenon Pharmaceuticals Inc Spiroheterocyclic compounds and their uses as therapeutic agents
MY158766A (en) 2005-04-11 2016-11-15 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
AU2006252781A1 (en) * 2005-06-02 2006-12-07 Janssen Pharmaceutica, N.V. Novel 3-spirocyclic indolyl derivatives useful as ORL-1 receptor modulators
KR20080012976A (ko) * 2005-06-17 2008-02-12 화이자 인코포레이티드 Ｏｒｌ1-수용기 길항제로서의 알파-(아릴- 또는헤테로아릴-메틸)-베타-피페리디노 프로판아마이드 화합물
EP1973543A2 (en) * 2005-12-22 2008-10-01 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
US8263605B2 (en) 2006-02-22 2012-09-11 Vertex Pharmaceutical Incorporated Modulators of muscarinic receptors
RU2008137593A (ru) * 2006-02-22 2010-03-27 Вертекс Фармасьютикалз Инкорпорейтед (Us) Модуляторы мускариновых рецепторов
GB0608452D0 (en) * 2006-04-27 2006-06-07 Glaxo Group Ltd Novel compounds
CN101500565A (zh) * 2006-06-29 2009-08-05 弗特克斯药品有限公司 毒蕈碱性受体的调节剂
CA2660903A1 (en) * 2006-08-15 2008-02-21 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
AU2007284350A1 (en) * 2006-08-18 2008-02-21 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
BRPI0719210A2 (pt) 2006-10-12 2015-05-05 Xenon Pharmaceuticals Inc Uso de compostos espiro-oxindol como agentes terapêuticos
AU2007325355A1 (en) * 2006-11-28 2008-06-05 Janssen Pharmaceutica N.V. Salts of 3-(3-amino-2-(R)-hydroxy-propyl)-1-(4-fluoro-phenyl)-8-(8-methyl-naphthalen-1-ylmethyl) -1,3,8-triaza-spiro[4.5]decan-4-one
WO2008124209A1 (en) 2007-04-09 2008-10-16 Janssen Pharmaceutica, N.V. 1,3,8-trisubstituted-1,3,8-triaza-spiro[4.5]decan-4-one derivatives as ligands of the orl-i receptor for the treatment of anxiety and depression
CA2700724A1 (en) * 2007-10-03 2009-04-09 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
CA2741024A1 (en) 2008-10-17 2010-04-22 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
SI2350090T1 (sl) 2008-10-17 2015-10-30 Xenon Pharmaceuticals Inc. Spojine spiro-oksindola in njihova uporaba kot terapevtska sredstva
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
KR20120099429A (ko) 2009-10-14 2012-09-10 제논 파마슈티칼스 인크. 스피로-옥스인돌 화합물의 합성 방법
UA107943C2 (en) * 2009-11-16 2015-03-10 Lilly Co Eli Compounds of spiropiperidines as antagonists of the orl-1 receptors
PE20121699A1 (es) 2010-02-26 2012-12-22 Xenon Pharmaceuticals Inc Composiciones farmaceuticas del compuesto espiro-oxindol para administracion topica
US9320729B2 (en) 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-flouro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative
US9855286B2 (en) 2012-05-18 2018-01-02 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-di methyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a salicylic acid component
US20130310435A1 (en) 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N, N-dimethyl-4-phenyl-4,9' -dihydro-3'H-spiro[cyclohexane-1,1' -pyrano[3,4,b]indol]-4-amine and Paracetamol or Propacetamol
US20130310385A1 (en) 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and Antidepressants
US9090618B2 (en) 2012-12-27 2015-07-28 Purdue Pharma L.P. Substituted benzimidazole-type piperidine compounds and uses thereof
WO2014102588A2 (en) 2012-12-27 2014-07-03 Purdue Pharma L.P. Indole and indoline-type piperidine compounds and uses thereof
WO2014102592A2 (en) 2012-12-27 2014-07-03 Purdue Pharma L.P. Oxime/substituted quinoxaline-type piperidine compounds and uses thereof
WO2014102590A1 (en) 2012-12-27 2014-07-03 Purdue Pharma L.P. Substituted piperidin-4-amino-type compounds and uses thereof
WO2014102589A1 (en) 2012-12-27 2014-07-03 Purdue Pharma L.P. Quinazolin-4(3h)-one-type piperidine compounds and uses thereof
TW201636017A (zh) 2015-02-05 2016-10-16 梯瓦製藥國際有限責任公司 以螺吲哚酮化合物之局部調配物治療帶狀疱疹後遺神經痛之方法
EP3383390A4 (en) * 2015-12-02 2019-11-20 Astraea Therapeutics, LLC PIPERIDINYL COMPOUNDS FOR NOCICEPTIN RECEPTOR
US10112924B2 (en) 2015-12-02 2018-10-30 Astraea Therapeutics, Inc. Piperdinyl nociceptin receptor compounds
CN106336357A (zh) * 2016-08-29 2017-01-18 启东东岳药业有限公司 2‑羟甲基丙烯酸甲酯的制备方法
CN110143918B (zh) * 2019-06-19 2020-08-04 青岛农业大学 3,4-二氢-3-(2-羟基苯甲酰)-2(1h)-喹啉酮活性骨架及合成方法和应用
CN113264949B (zh) * 2021-05-31 2022-04-05 西南大学 一类螺苯并噁嗪哌啶α,β-不饱和酮类衍生物的设计合成与应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4562799A (en) 1998-06-15 2000-01-05 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
ID29137A (id) * 1998-07-27 2001-08-02 Schering Corp Ligan-ligan afinitas tinggi untuk reseptor nosiseptin orl-1
ES2316559T3 (es) * 2001-04-18 2009-04-16 Euro-Celtique S.A. Compuestos espiroindeno y espiroindano.
US20030078278A1 (en) * 2001-06-26 2003-04-24 Pfizer Inc. Spiropiperidine compounds as ligands for ORL-1 receptor

Also Published As

Publication number Publication date
US6869960B2 (en) 2005-03-22
TW200302725A (en) 2003-08-16
UY27623A1 (es) 2003-08-29
GT200300014A (es) 2003-08-22
CA2466915A1 (en) 2003-08-07
MXPA04007242A (es) 2004-10-29
EP1470126A1 (en) 2004-10-27
BR0307268A (pt) 2004-12-14
US20030158219A1 (en) 2003-08-21
JP2005519921A (ja) 2005-07-07
PE20030848A1 (es) 2003-10-11
PA8564201A1 (es) 2003-12-10
WO2003064425A1 (en) 2003-08-07

Similar Documents

Publication Publication Date Title
AR038235A1 (es) Compuestos de espiropiperidina n-sustituidos como ligandos para el receptor orl-1
AR054090A1 (es) Derivados de quinuclidina como antagonistas del receptor muscarinico m3. composiciones farmaceuticas y proceso de obtencion
AR015528A1 (es) Compuestos heterociclicos como inhibidores de enzimas rotamasas, composiciones, su uso para la preparacion de medicinas, proceso para su preparacion ycompuestos intermediarios
ECSP056016A (es) Nuevos derivados de 2-piridinacarboxamida
AR055878A1 (es) Derivados de ciclopropanocarboxamida
AR052943A1 (es) Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida
AR041303A1 (es) Compuestos de piperidinil-imidazopiridina n-sustituidos como moduladores del receptor 5-ht4"
ATE293101T1 (de) Piperidine zur verwendung als orexin rezeptor antagonisten
AR022303A1 (es) Derivados de piperidina, tetrahidropiridina y piperazina, su preparacion y utilizacion
EA199800404A1 (ru) Производные 1-(1,2-дизамещенный пиперидинил)-4-замещенного пиперазина
AR045931A1 (es) Derivados de piperazina
PE20091884A1 (es) Antagonistas de cgrp seleccionados, procedimiento para su preparacion, asi como su uso como medicamento
CO5700720A2 (es) Derivados de n-(quinolin-5l) alquilamida-sustituida; n-alquilquinolin-5-carboxamida-sustituida; n-alquilisoquinolin-5-carboxamida-sustituida; n-(isoquinolin-5-yl) alquilamida-sustituida y procesos para su preparacion
PE53097A1 (es) Nuevos derivados de arilglicinamida, procedimientos para su preparacion, y composiciones farmaceuticas que contienen estos compuestos
NO964700L (no) Nye aminosyrederivater, fremgangsmåte til deres fremstilling og farmasöytiske blandinger som inneholder disse forbindelser
AR071763A1 (es) Pirazoles trisustituidos, composiciones farmaceuticas que los contienen, y usos de los mismos en el tratamiento de trastornos neurologicos y psiquiatricos
NO20073729L (no) Heterocykliske forbindelser som CCR2B-antagonister
ES2476422T3 (es) Compuestos de piperidina 3,5-sustituida como inhibidores de renina
PE20001303A1 (es) Derivados de la 4-aroilpiperidina como antagonistas del receptor ccr-3
ATE524432T1 (de) Aminverbindung und deren verwendung für medizinische zwecke
BR0013498A (pt) Composto, método para a preparação do mesmo, composição farmacêutica, e, métodos para a preparação da mesma e para o tratamento de distúrbios do snc
AR053435A1 (es) Derivados de 5-amminoindol, un metodo para su preparacion, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un madicamento para el tratamiento de enfermedades asociadas a la modulacion de receptores h3.
AR042362A1 (es) Derivados de 3h-quinazolin-4-ona, proceso de obtencion y composiciones farmaceuticas que los contienen
EA200501148A1 (ru) Пиридилоксиметильные и бензизоксазольные азабициклические производные
AR033942A1 (es) Compuestos de monofluoroalquilo aplicables en la potenciacion de los compuestos intermediarios utilizables en la sintesis de dichos compuestos de monofluoralquilo; composiciones farmaceuticas formuladas con dichos compuestos potenciadores y metodos para la potenciacion de las funciones de dichos rec

Legal Events

Date Code Title Description
FA Abandonment or withdrawal